COSMOS Pharmaceutical Corporation
3349.T · JPX
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Revenue | ¥272,394,000 | ¥259,122,000 | ¥246,332,000 | ¥244,095,000 |
| % Growth | 5.1% | 5.2% | 0.9% | – |
| Cost of Goods Sold | ¥215,219,000 | ¥205,049,000 | ¥193,198,000 | ¥192,584,000 |
| Gross Profit | ¥57,175,000 | ¥54,073,000 | ¥53,134,000 | ¥51,511,000 |
| % Margin | 21% | 20.9% | 21.6% | 21.1% |
| R&D Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| G&A Expenses | ¥0 | ¥107,000 | ¥0 | ¥0 |
| SG&A Expenses | ¥45,529,000 | ¥24,506,000 | ¥41,850,000 | ¥42,635,000 |
| Sales & Mktg Exp. | ¥0 | ¥1,561,000 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥20,791,000 | ¥0 | ¥112,000 |
| Operating Expenses | ¥45,529,000 | ¥45,297,000 | ¥41,850,000 | ¥42,747,000 |
| Operating Income | ¥11,646,000 | ¥8,776,000 | ¥11,284,000 | ¥8,764,000 |
| % Margin | 4.3% | 3.4% | 4.6% | 3.6% |
| Other Income/Exp. Net | ¥442,000 | ¥410,000 | ¥459,000 | ¥613,000 |
| Pre-Tax Income | ¥12,088,000 | ¥9,186,000 | ¥11,743,000 | ¥9,377,000 |
| Tax Expense | ¥3,916,000 | ¥551,000 | ¥3,828,000 | ¥3,092,000 |
| Net Income | ¥8,171,000 | ¥8,635,000 | ¥7,915,000 | ¥6,285,000 |
| % Margin | 3% | 3.3% | 3.2% | 2.6% |
| EPS | 103.09 | 108.95 | 99.86 | 79.3 |
| % Growth | -5.4% | 9.1% | 25.9% | – |
| EPS Diluted | 103.09 | 108.95 | 99.86 | 79.3 |
| Weighted Avg Shares Out | 79,257 | 79,257 | 79,257 | 79,257 |
| Weighted Avg Shares Out Dil | 79,257 | 79,257 | 79,257 | 79,257 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥27,000 | ¥12,000 | ¥14,000 | ¥11,000 |
| Interest Expense | ¥110,000 | ¥109,000 | ¥48,000 | ¥48,000 |
| Depreciation & Amortization | ¥5,748,000 | ¥6,013,000 | ¥5,630,000 | ¥5,293,000 |
| EBITDA | ¥17,947,000 | ¥15,306,000 | ¥17,421,000 | ¥14,169,000 |
| % Margin | 6.6% | 5.9% | 7.1% | 5.8% |